Adjunctive therapy for calciphylaxis progressing despite sodium thiosulfate

Calciphylaxishard

A 56-year-old man on hemodialysis for 1.5 years with type 2 diabetes, hypertension, and atrial fibrillation is diagnosed with calciphylaxis of both calves. His medications include apixaban, fosinopril, insulin, and sevelamer. Calcitriol is stopped and sodium thiosulfate is started three times weekly with dialysis, but his pain worsens and the lesions ulcerate into large stellate plaques with thick black eschar, without surrounding erythema or purulence. Calcium 8.9 mg/dL, phosphorus 4.7 mg/dL, albumin 3.2 g/dL, intact PTH 132 pg/mL (dialysis target 130–585), 25-hydroxyvitamin D 18 ng/mL, Kt/V 1.7. What is the most appropriate next step in management?

  1. A.Change apixaban to warfarin
  2. B.Hyperbaric oxygenCorrect
  3. C.Cholecalciferol
  4. D.Surgical debridement

Explanation

The most appropriate next step is hyperbaric oxygen therapy. This patient has calciphylaxis that is progressing despite sodium thiosulfate, withdrawal of calcitriol, adequate dialysis (Kt/V 1.7), and controlled calcium and phosphorus. Calciphylaxis results from medial calcification and intimal fibrosis of small cutaneous arterioles with superimposed thrombosis, producing ischemic necrosis of skin and subcutaneous fat. Hyperbaric oxygen raises tissue oxygen tension in hypoxic wound beds, promotes angiogenesis and fibroblast function, and improves leukocyte bactericidal activity. Observational series, including a large single-center experience, report wound healing or improvement in a majority of patients treated, and expert reviews recommend it as an adjunct for nonhealing or progressive wounds when available. Multimodal care should continue: sodium thiosulfate, pain control, nutritional support, avoidance of trauma, and specialized wound care. Changing apixaban to warfarin would be harmful. Warfarin inhibits vitamin K–dependent carboxylation of matrix Gla protein, a key inhibitor of vascular calcification, and is one of the strongest risk factors for calciphylaxis; in patients with calciphylaxis who need anticoagulation, warfarin should be switched to a direct oral anticoagulant, not the reverse. Cholecalciferol to correct 25-hydroxyvitamin D deficiency is reasonable in dialysis patients generally, but it does not treat progressive calciphylaxis, and any vitamin D therapy is usually deferred in active disease to avoid raising calcium and phosphorus. Surgical debridement is reserved for wounds with infection, liquefied necrosis, or nonviable tissue causing sepsis. A dry, adherent eschar without erythema or purulence acts as a protective barrier, and aggressive debridement of ischemic tissue can enlarge wounds that cannot heal because of poor perfusion. Gentle, selective debridement may be considered later as part of specialized wound care.

Why each option

A.
Warfarin inhibits matrix Gla protein carboxylation and is a major calciphylaxis risk factor; anticoagulated patients should move from warfarin to a direct oral anticoagulant.
B.
Correct. For calciphylaxis progressing despite sodium thiosulfate and calcitriol withdrawal, hyperbaric oxygen improves oxygenation of ischemic wounds and shows healing benefit in observational series.
C.
Cholecalciferol corrects vitamin D deficiency but does not treat calciphylaxis and is usually deferred during active disease to avoid raising calcium and phosphorus.
D.
Dry, adherent eschar without erythema or purulence protects ischemic tissue; aggressive debridement is reserved for infected or liquefied necrotic wounds.

Reference: Nigwekar SU, N Engl J Med 2018 (calciphylaxis review); An J, Nephrology (Carlton) 2015 (hyperbaric oxygen in the treatment of calciphylaxis, case series)

This is one of 1,100 questions in the MedBoardSA nephrology bank, with timed test mode, tutor mode, and progress tracking by topic.

Practise the full bank

Browse other topics